Table 1.
Clinical and biological characteristics of the retrospective study population as a whole and according to the vaccine response status.
| Whole population | Normala polysaccharide (PS) response (good responders) | Impaireda PS response (poor responders) | p | |
|---|---|---|---|---|
| n = 62 | n = 20 (32.3%) | n = 42 (67.7%) | ||
| Demographics | ||||
| Age (years) | 37.5 (18–75) | 30 (18–75) | 41 (18–70) | 0.065 |
| Gender (women) n = (%) | 33 (53.2%) | 9 (45.0%) | 24 (57.1%) | 0.370 |
| Diagnosis n = (%) | ||||
| Common variable immunodeficiency | 5 (8.1%) | 0 (0.0%) | 5 (11.9%) | 0.165 |
| Unclassified, isolated immunoglobulin G (IgG) deficiency | 7 (11.3%) | 2 (10.0%) | 5 (11.9%) | 1.000 |
| IgG sub-class deficiency | 8 (12.9%) | 2 (10.0%) | 6 (14.3%) | 1.000 |
| IgG1/3 deficiency | 3 (4.8%) | 1 (5.0%) | 2 (4.8%) | 1.000 |
| IgG2 deficiency | 2 (3.2%) | 1 (5.0%) | 1 (2.4%) | 0.545 |
| IgG2/A deficiency | 3 (4.8%) | 0 (0.0%) | 3 (7.2%) | 0.445 |
| Isolated IgA deficiency | 2 (3.2%) | 1 (5.0%) | 1 (2.4%) | 0.480 |
| Isolated IgM deficiency | 1 (1.6%) | 0 (0.0%) | 1 (2.4%) | 1.000 |
| Specific PS antibody deficiency | 24 (38.7%) | 0 (0.0%) | 24 (57.1%) | <0.001 |
| Noimmunodeficiency diagnosed | 15 (24.2%) | 15 (75.0%) | 0 (0.0%) | <0.001 |
| PS response | ||||
| Time interval between immunization and sample collection (weeks) | 6.3 (4.0–7.9) | 6.0 (4.0–7.8) | 6.4 (4.1–7.9) | 0.465 |
| Serotype-specific assay (SSA) | ||||
| Number of good responses | 3 (0–7) | 6 (5–7) | 2 (0–4) | <0.001 |
| Overall assay (OVA) (mg/L) | ||||
| Pre-immunization OVA antibody titer | 26 (4–196) | 47.5 (12–196) | 22.5 (4–166) | 0.004 |
| Post-immunization OVA antibody titer | 151 (9–1360) | 480 (114–1360) | 100 (9–1010) | <0.001 |
| Post-immunization increase in titer | 121 (0–1325) | 412.5 (85–1325) | 69 (0–846) | <0.001 |
| Post-/pre-immunization titer ratio | 4.8 (0.8–38.9) | 9.3 (2.9–38.9) | 3.9 (0.8–16.5) | <0.001 |
aNormal and impaired PS responses as assessed by the serotype-specific assay and using the American Academy of Asthma, Allergy and Immunology criteria (2).
The data are quoted as the median (range) or the number (percentage).
p-Values were obtained using a Mann–Whitney test for quantitative variables and a chi-square or Fisher’s exact test for qualitative variables.
Significant p-values are highlighted in bold font.